Warfarin Outcomes in China

Risks & contraindications

Background

Highlighted claims

• The trial was conducted at five centres representing multiple hospital levels in Hunan Province, China, from March 2021 to March 2023. — Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial
• Ischaemic stroke attributable to warfarin occurs in 5.23% of Chinese patients versus a global average of 2.07%, and intracranial haemorrhage in 2.94% versus 0.63% globally. — Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial
• The dominant warfarin management model in China is usual care, where physicians handle dose adjustments for large patient panels with limited capacity for patient education. — Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial
• High clinical workloads leave physicians in China with limited capacity for patient education in warfarin management. — Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial